Mr. Reddy oversees the venture and growth equity strategies of Tarsadia as a Managing Director. Prior to April 2018, he served as an Observer on the Cue Board of Directors until September 2021. Furthermore, the Board plans to start the process of appointing an extra independent director who is well competent to the Board.
The CEO and chairman of Cue, Ayub Khattak, stated that the company is still committed to generating value for all of its stakeholders. “We are excited to work with Rishi going ahead and to hear more from him as a director.
According to Mr. Reddy, Cue’s cutting-edge technology has the power to revolutionize the diagnosis and treatment of both acute and chronic illnesses. The main shareholder in Cue, Tarsadia, thinks there is a chance to generate a lot of value for shareholders, which is why I am joining the board. He was excited to collaborate with the Board and help the management group carry out plans to enhance the organization’s cost structure and promote increased operational effectiveness.
Mr. Reddy’s appointment brings the total number of directors on Cue’s board to eight. Cue will file a Current Report on Form 8-K with the Securities and Exchange Commission, and the entire Cooperation Agreement between Cue and Tarsadia will be an exhibit to that report.
As a managing director of Tarsadia Investments, Mr. Reddy is committed to forming long-lasting, game-changing partnerships with businesses in the fintech and healthtech sectors. Mr. Reddy founded and served as CEO of DigiPath Solutions, a pioneer in the field of digital anatomic pathology, before joining Tarsadia. He assisted in developing the venture and growth practice at Tarsadia after joining. Currently, Mr. Reddy is an observer on the boards of BoltTech, YieldStreet, Petal, AvantStay, Phil, Chronus Health, Fathom, Continental Hospitals, and Envisics. He graduated with a B.S. in Management from Babson College and an M.B.A. from the Wharton School of the University of Pennsylvania.
Cue Health Inc. is a healthcare technology firm that enables people to live the healthiest lifestyles possible through diagnostic-enabled treatment. In addition to on-demand telehealth consultations and treatment choices for a variety of health and wellness requirements, the Cue Health platform provides accessible and tailored access to lab-quality diagnostic testing at home and at the point-of-care for both individuals and healthcare providers. Cue’s clientele consists of both federal and state government organizations as well as businesses, consumers, and healthcare professionals in the private sector. The U.S. Food and Drug Administration (FDA) granted Cue De Novo authorization for their COVID-19 test, making it the first respiratory test intended for home use to obtain this approval. Additionally, the FDA granted Cue an Emergency Use Authorization to utilize its molecular mpox test at the point-of-care. Cue has submitted additional applications to the FDA for consideration in order to further expand its test menu. These submissions include the Cue® Flu + COVID-19 Molecular Test and the Cue® RSV Molecular Test, which are intended for usage both at-home and at points of care. Founded in 2010, Cue is based in San Diego and has more than 100 patents under its name.
